Kalbe Farma Tbk PT (KLBF)

Jakarta
Currency in IDR
1,500
-15(-0.99%)
Closed·
KLBF Scorecard
Full Analysis
Management has been aggressively buying back shares
KLBF is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,4851,530
52 wk Range
9851,795
Key Statistics
Edit
Bid/Ask
1,500.00 / 1,505.00
Prev. Close
1,515
Open
1,510
Day's Range
1,485-1,530
52 wk Range
985-1,795
Volume
62.57M
Average Volume (3m)
49.66M
1-Year Change
-4.46%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KLBF Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1,659
Upside
+10.60%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry

Kalbe Farma Tbk PT News & Analysis

Show more

Kalbe Farma Tbk PT Company Profile

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic divisions. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products. It operates Mitrasana Clinics, a health care service. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. The company was incorporated in 1966 and is based in Jakarta, Indonesia.

Employees
12841
Market
Indonesia

Compare KLBF to Peers and Sector

Metrics to compare
KLBF
Peers
Sector
Relationship
P/E Ratio
20.4x16.7x−0.5x
PEG Ratio
1.161.220.00
Price/Book
2.9x2.9x2.6x
Price / LTM Sales
2.1x1.9x3.0x
Upside (Analyst Target)
8.3%15.0%52.4%
Fair Value Upside
Unlock16.6%8.7%Unlock

Analyst Ratings

12 Buy
2 Hold
1 Sell
Ratings:
15 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1,659
(+10.60% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 72.97%
Dividend Yield
2.40%
Industry Median 6.63%
Annualised payout
36.00
Paid annually
5-Years Growth
+6.72%
Growth Streak

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
20.60 / 18.63
Revenue / Forecast
8.845T / --
EPS Revisions
Last 90 days

KLBF Income Statement

People Also Watch

1,105
TINS
-0.90%
120
BUMI
-0.83%
3,250
INCO
-1.81%
1,430
MEDC
-1.38%

FAQ

What Is the Kalbe Farma (KLBF) Stock Price Today?

The Kalbe Farma stock price today is 1,500.00

What Stock Exchange Does Kalbe Farma Trade On?

Kalbe Farma is listed and trades on the Jakarta Stock Exchange stock exchange.

What Is the Stock Symbol for Kalbe Farma?

The stock symbol for Kalbe Farma is "KLBF."

Does Kalbe Farma Pay Dividends? What’s The Current Dividend Yield?

The Kalbe Farma dividend yield is 2.4%.

What Is the Kalbe Farma Market Cap?

As of today, Kalbe Farma market cap is 68.38T.

What Is Kalbe Farma's Earnings Per Share (TTM)?

The Kalbe Farma EPS (TTM) is 72.97.

When Is the Next Kalbe Farma Earnings Date?

Kalbe Farma will release its next earnings report on 30 July 2025.

From a Technical Analysis Perspective, Is KLBF a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Kalbe Farma Stock Split?

Kalbe Farma has split 7 times.

How Many Employees Does Kalbe Farma Have?

Kalbe Farma has 12841 employees.

What is the current trading status of Kalbe Farma (KLBF)?

As of 21 June 2025, Kalbe Farma (KLBF) is trading at a price of 1,500.00, with a previous close of 1,515.00. The stock has fluctuated within a day range of 1,485.00 to 1,530.00, while its 52-week range spans from 985.00 to 1,795.00.

What Is Kalbe Farma (KLBF) Price Target According to Analysts?

The average 12-month price target for Kalbe Farma is IDR1659, with a high estimate of IDR2200 and a low estimate of IDR1410. 12 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +10.60% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.